The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Updates

Drug Updates

January 1, 2009 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On June 27, Centocor submitted a BLA for golimumab to treat adults with active RA, psoriatic arthritis, and ankylosing spondylitis. Golimumab is administered as a monthly SC injection. An IV infusion therapy is also being investigated. Additionally, an application was submitted in Europe for the same indications.16

You Might Also Like
  • Drug Updates: Citalopram hydrobromide, Statins, and More
  • Drug Updates
  • Rheumatology Drug Updates
Explore This Issue
January 2009
Also By This Author
  • Antirheumatic Drugs May Be Linked to Pulmonary Toxicity & More

The FDA has sent a complete response letter to Roche regarding their BLA application for IV tocilizumab (Actemra), submitted to treat adult patients with moderate to severely active RA.17 Five trials involving more than 4,000 patients have been conducted, with one still ongoing. In the completed Phase 3 trials, primary endpoints have been met.18

Monitoring and Management

Other than avoiding use of a statin, there are no known therapies to prevent statin-induced myopathy.1,3 CoQ10 supplementation lacks strong scientific support for improving statin-induced myopathy and therefore is not widely recommended.1,2

Routine CK monitoring is not recommended, but baseline CK level may be obtained prior to commencing statin therapy in high-risk patients, or those already on agents known to cause myopathy.1,7 Symptoms of myalgia should be monitored during statin therapy with an attempt to use the lowest dose.1 Consider obtaining a CK level in patients with muscle-related symptoms. Discontinue the statin if a patient has a CK level > 10 X ULN with muscle soreness, tenderness, or pain. Evaluate muscle symptoms six to 12 weeks after starting therapy and at each follow-up appointment.3

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The role of other causes of myopathy (e.g., hypothyroidism, trauma, seizures, infection, drug abuse, dermatomyositis, strenuous activity) should be ruled out. A thyroid-stimulating hormone level and a careful neurologic examination should be obtained, as well as a lipid panel.1,4,11 The use of other medications and herbal therapies should also be ascertained. If specific rheumatologic disorders are suspected, more specific tests should be ordered (e.g., ESR, ANA, CRP, anti-Jo antibody).4 Both myalgia and arthralgia are reversible upon drug discontinuation, usually within two to three weeks.8 Remember to also follow liver enzymes in these patients, obtaining them initially and then approximately every 12 weeks thereafter, then annually or more frequently if needed.3

In patients who report intolerable myalgia regardless of CK levels, discontinue the statin. A rechallenge with that or another statin may be attempted. In patients with moderate to severe CK elevations or rhabdomyolysis, the statin should be discontinued. Use of a lower-dose hydrophilic statin is still considered risky.4 Patients with clinically significant rhabdomyolysis need to be hospitalized for intravenous (IV) hydration and urine alkalinization.1 Many patients intolerant of statins will be intolerant of ezetimibe.1,4 Bile acid sequestrants and resins may be the safest choice for these to lower cholesterol.1,4

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Drug Updates, Safety Tagged With: Labeling Changes, Myopathy, Pharmaceutical Research, SafetyIssue: January 2009

You Might Also Like:
  • Drug Updates: Citalopram hydrobromide, Statins, and More
  • Drug Updates
  • Rheumatology Drug Updates
  • Drug Updates

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)